Weinstein SF, et al. - In a pivotal, phase 2b study, dupilumab (an anti-IL-4Rα monoclonal antibody) reduced severe exacerbations, improved lung function and quality of life, and was generally well tolerated in patients with uncontrolled persistent asthma despite using medium-to-high-dose inhaled corticosteroids plus long-acting β2-agonists. This study was performed on asthma patients with comorbid perennial allergic rhinitis (PAR), with an intent to delineate the impact of dupilumab on the 22-item Sino-Nasal Outcome Test (SNOT-22) total score and its allergic rhinitis (AR)-associated items in these subjects. Significant improvement was noted in AR-associated nasal symptoms in patients with uncontrolled persistent asthma and comorbid PAR who were treated with dupilumab 300 mg q2w.